1
by Foerster, Vicki, Perras, Christine, Spry, Carolyn, Weeks, Laura Christine
Published 2015
Canadian Agency for Drugs and Technologies in Health
... Canadians. Public health interventions to reduce the secondary spread of measles are vaccination...

2
by Foerster, Vicki, Perras, Christine, Spry, Carolyn, Weeks, Laura Christine
Published 2015
Canadian Agency for Drugs and Technologies in Health
... Canadians. Public health interventions to reduce the secondary spread of measles are vaccination...

4
by Membe, Stephen K.
Published 2011
Canadian Agency for Drugs and Technologies in Health
... are transfused annually in Canada, the widespread implementation of Octaplas may have significant public health...

5
Published 2014
Canadian Agency for Drugs and Technologies in Health
...The nosocomial transmission of tuberculosis (TB) in healthcare facilities is a major public health...

6
Published 2014
Canadian Agency for Drugs and Technologies in Health
...The nosocomial transmission of tuberculosis (TB) in healthcare facilities is a major public health...

7
Published 2019
Canadian Agency for Drugs and Technologies in Health
... the Canadian public health care payer perspective and used four-week cycles over a 10-year time horizon...

8
by Li, Ke Xin, Argáez, Charlene
Published 2020
Canadian Agency for Drugs and Technologies in Health
...In 2019, there were 372,329 babies born in Canada. Public health early child home visiting programs...

9
Published 2019
Canadian Agency for Drugs and Technologies in Health
... lifetime horizon, from the perspective of a Canadian public health care payer)...

10
by Li, Ke Xin, Argáez, Charlene
Published 2020
Canadian Agency for Drugs and Technologies in Health
...In 2019, there were 372,329 babies born in Canada. Public health early child home visiting programs...

11
Published 2019
Canadian Agency for Drugs and Technologies in Health
... the Canadian public health care payer perspective and used four-week cycles over a 10-year time horizon...

12
Published 2018
Canadian Agency for Drugs and Technologies in Health
... horizon -- conducted from a Canadian public health care payer perspective -- which compared ozenoxacin...

13
Published 2018
Canadian Agency for Drugs and Technologies in Health
... horizon -- conducted from a Canadian public health care payer perspective -- which compared ozenoxacin...

14
Published 2020
Canadian Agency for Drugs and Technologies in Health
... lifetime time horizon (86 years) from the perspective of the public health care payer. A discount of 1.5...

15
Published 2016
CADTH
... the perspective of the Canadian public health care payer. The manufacturer reported that ticagrelor + ASA...

16
Published 2019
CADTH
... horizon using a three-month cycle length. The analysis adopted a Canadian public health care system...

17
Published 2019
CADTH
... horizon using a three-month cycle length. The analysis adopted a Canadian public health care system...

18
Published 2019
CADTH
.... Surveillance data from the Public Health Agency of Canada estimates that, at the end of 2016, there were...

19
Published 2019
CADTH
.... Surveillance data from the Public Health Agency of Canada estimates that, at the end of 2016, there were...

20
Published 2018
Canadian Agency for Drugs and Technologies in Health
... with dietary restriction alone in infants less than 30 days of age over a six-year time horizon, from a public...